CD44 drives aggressiveness and chemoresistance of a metastatic human osteosarcoma xenograft model.
Author | |
---|---|
Abstract | :
Osteosarcoma is the most common primary malignant bone tumor with a 5 year survival rate of up to 70%. However, patients with metastatic disease have still a very poor prognosis. Osteosarcoma metastasis models are essential to develop novel treatment strategies for advanced disease. |
Year of Publication | :
2017
|
Journal | :
Oncotarget
|
Volume | :
8
|
Issue | :
69
|
Number of Pages | :
114095-114108
|
Date Published | :
2017
|
DOI | :
10.18632/oncotarget.23125
|
Short Title | :
Oncotarget
|
Download citation |